secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-035830
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance
--------------------------------------------------------------------------------

- Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.
- Net income $0.3M vs net loss of $3.3M in Q2 2023; adjusted EBITDA $1.5M vs negative $2.3M.
- Generated $1.4M in cash flow from operations; cash and equivalents rose to $11.9M from $8.6M.
- FY 2024 net product sales guidance raised to $95M–$98M (from $90M–$94M) and Adjusted EBITDA to $0.75M–$1.5M.
- Promoted Tim Chole to Chief Commercial Officer; amended Evoqua asset purchase agreement for extended payment terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828024035830/0001628280-24-035830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828024035830/rmti-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer